Meriofert Set (Follicle-Stimulating Hormone, Luteinising Hormone)

The FSH component binds to FSH receptors on ovarian granulosa cells, stimulating follicular growth and estradiol production. The LH component binds to LH receptors on theca and luteal cells, promoting androgen conversion, final follicle maturation, and luteinization, together enabling ovulation.

The dose of Meriofert Set is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s clinical condition, response to therapy, and monitoring results.

Meriofert Set is not indicated for use during pregnancy and its safety in breastfeeding has not been established. It should be avoided in pregnant women, and caution is advised for nursing mothers; the prescriber should evaluate risks and benefits.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Meriofert Set combines recombinant FSH and LH, whereas many alternatives provide only FSH (e.g., recombinant FSH alone) or are derived from urinary sources. The combined formulation can more closely mimic natural pituitary secretion, potentially improving follicular response in certain protocols, but choice depends on clinical goals and physician preference.

Meriofert Set must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Once prepared for injection, it should be used within the time frame specified in the product label and kept in the original packaging to maintain stability.

Meriofert Set is given by subcutaneous injection, typically into the abdominal wall or thigh. The product may require reconstitution with a supplied diluent before injection. Administration technique and injection sites should follow the prescribing information and be performed by trained healthcare personnel.

The most serious risks include severe ovarian hyperstimulation syndrome, which can cause rapid weight gain, respiratory distress, and thromboembolic complications, ovarian torsion presenting as acute pelvic pain, and systemic allergic reactions such as anaphylaxis. Prompt medical attention is required if any of these occur.

Meriofert Set should not be used in patients with known hypersensitivity to any component, active ovarian cysts, uncontrolled thyroid disease, pregnancy, or those with severe ovarian failure where stimulation would be ineffective. Contraindications are detailed in the prescribing information and should be reviewed by the prescriber.